WIKIMEDIA, TOM VARCOReports from clinical trials for breast cancer drugs are often rife with bias and spin, according to a study published this week (January 9) in Annals of Oncology.

Researchers from the University of Toronto analyzed the publications from 164 randomized Phase III clinical trials and found that a third were reported positively despite not meeting the primary objective, by emphasizing other, less important outcomes. “These reports were biased and used spin in attempts to conceal that bias,” the authors wrote. Some studies even changed the primary objective halfway through, possibly because early results suggested the trial would otherwise fail.

The researchers also found evidence of bias in the reporting of toxic side effects in two-thirds of the trials, particularly in trials that found the treatment was effective for its primary objective. In these cases, high toxicity findings were omitted from the abstracts and conclusions, and instead...

The authors conclude that journal editors, regulators, and reviewers should apply a more critical eye to trial reports. Meanwhile, Richard Francis, research manager at UK-based charity Breakthrough Breast Cancer, told The Telegraph: “We strongly believe that making clinical trial data freely available would decrease the potential for spin by allowing more researchers to investigate the results.”

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?